


AMENDMENTS TO CLAIMS

Claim 1. (Original) A compound of the formula I



wherein

Ar¹ is a substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;


X is a linking group selected from alkylene, CO, alkyleneCO, OCO, alkyleneOCO, SO₂ and alkyleneSO₂;

J is a linking group selected from S, SO and SO₂;

R¹ and R² are each independently substituted or unsubstituted C₁-C₄ alkyl, or R¹ can be cyclized with R² to form (-CH₂-)_m where m is an integer from 2 to 5;

R³ is hydrogen(H) or alkyl;

Q is Ar¹ or G;



z is 1 or 2;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen(H), halo, haloalkyl, alkyl, alkoxy, haloalkoxy, hydroxy, cyano, nitro, amino, alkylamino and alkylthio;

R⁷ and R⁸ are each independently selected from hydrogen(H), alkyl, aryl and heteroaryl; including all prodrug esters, pharmaceutically acceptable salts or stereoisomers thereof.

Claim 2. (Original) The compound as defined in claim 1 wherein

X is alkylene;

J is sulfur(S);

R¹ and R² are methyl, or R¹ is cyclized with R² to form a cyclopropyl ring;

R³ is hydrogen;







z is 2;





Q is substituted or unsubstituted phenyl or naphthyl, or G;

R⁴, R⁵ and R⁶ are hydrogen; and


R⁷ and R⁸ are hydrogen.

Claim 3. (Currently Amended) The compound as defined in claim 1 wherein the compound is selected from:





Claim 4. (Currently Amended) The compound as defined in claim 1 wherein the compound is selected from:



Claim 5. (Original) A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

Claim 6. (Original) The pharmaceutical composition of claim 5 further comprising at least one additional therapeutic agent selected from other compounds of formula I, anti-osteoporosis agents, cholesterol/lipid lowering agents, growth promoting agents, progesterone receptor agonists, modulators of bone resorption, selective estrogen receptor modulators, selective androgen receptor modulators, anti-resorptive agents, hormone replacement therapies, vitamin D, vitamin D analogues, elemental calcium, calcium supplements, cathepsin K inhibitors, MMP inhibitors, vitronectin receptor antagonists, Src SH₂ antagonists, Src kinase inhibitors, vacuolar H⁺-ATPase inhibitors, PTH, PTH analogues and fragments, osteoprotegerin, Tibolone, p38 inhibitors, prostanoids, PPAR gamma antagonists and isoflavinoids.


Claim 7. (Withdrawn) A method for treating or delaying the progression or onset of hypoparathyroidism, osteosarcoma, chondrosarcoma, periodontal disease, fracture healing, osteoarthritis, Paget's disease, osteopenia, glucocorticoid induced osteoporosis, osteomalacia, osteoporosis, metastatic bone disease or joint replacement, which comprises administering to a

mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

Claim 8. (Withdrawn) The method according to claim 7 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from other compounds of formula I, anti-osteoporosis agents, cholesterol/lipid lowering agents, growth promoting agents, progesterone receptor agonists, modulators of bone resorption, selective estrogen receptor modulators, selective androgen receptor modulators, anti-resorptive agents, hormone replacement therapies, vitamin D, vitamin D analogues, elemental calcium, calcium supplements, cathepsin K inhibitors, MMP inhibitors, vitronectin receptor antagonists, Src SH₂ antagonists, Src kinase inhibitors, vacuolar H⁺-ATPase inhibitors, PTH, PTH analogues and fragments, osteoprotegerin, Tibolone, p38 inhibitors, prostanoids, PPAR gamma antagonists and isoflavinoids.

Claim 9. (Withdrawn) A method of enhancing bone formation in a mammalian species comprising administering a therapeutically effective amount of a compound as defined in Claim 1 to a patient in need thereof.

Claim 10. (Currently Amended) A pharmaceutical composition capable of modulating the calcium sensing receptor comprising a compound of formula I



wherein

Ar¹ is a substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;


X is a linking group selected from alkylene, CO, alkyleneCO, OCO, alkyleneOCO, SO₂ and alkyleneSO₂;

J is a linking group selected from S, SO and SO₂;

R¹ and R² are each independently substituted or unsubstituted C₁-C₄ alkyl, or R¹ can be cyclized with R² to form (-CH₂)_m where m is an integer from 2 to 5;

R³ is hydrogen(H) or alkyl;

Q is Ar¹ or G;



z is 1 or 2;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen(H), halo, haloalkyl, alkyl, alkoxy, haloalkoxy, hydroxy, cyano, nitro, amino, alkylamino and alkylthio;

R⁷ and R⁸ are each independently selected from hydrogen(H), alkyl, aryl and heteroaryl;

including all prodrug esters, pharmaceutically acceptable salts or stereoisomers thereof and a pharmaceutically acceptable carrier therefor.

Claim 11. (Currently Amended) The pharmaceutical composition of claim 10 wherein said composition compound is a calcium sensing receptor antagonist.